Report cover image

Hemoglobinopathies Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

Publisher IMARC Services Pvt. Ltd.
Published May 29, 2023
Length 143 Pages
SKU # IMRC17986285

Description

Hemoglobinopathies Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028


The global hemoglobinopathies market size reached US$ 9.2 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 16.3 Billion by 2028, exhibiting a growth rate (CAGR) of 9.39% during 2023-2028.

Hemoglobinopathies is genetic blood disorder that causes structural and production abnormalities in hemoglobin molecules. Sickle cell, thalassemia, hemoglobin C, and beta-thalassemia are some of the common types of hemoglobinopathies. Hemoglobinopathies are detected by genetic testing, hemoglobin by high-performance liquid chromatography, routine red blood cell (RBC) count, hemoglobin isoelectric focusing (Hb IEF), and hemoglobin electrophoresis (Hb ELP) test. Pale skin, shortness of breath, cold hands or feet, tiredness, pain, and swelling in the hands and feet are a few of the most common symptoms hemoglobinopathies. Some of the widely used hemoglobinopathies treatment solutions include antibiotics, ACE inhibitors, stem-cell transplantation, blood transfusions, hydroxyurea, and analgesic.

Hemoglobinopathies Market Trends:



The increasing prevalence of various medical conditions, such as sickle cell disease (SCD) and thalassemia, is one of the key factors driving the growth of the market. Hemoglobinopathies are caused by abnormal hemoglobin that deforms and damages red blood cells and makes them hard and sticky. In line with this, the rising prevalence of anemia, especially among the geriatric population, which is also susceptible to various other chronic ailments, is favoring the market growth. Various technological advancements, such as the development of CRISPR-Cas9 technology to cure hemoglobinopathies by editing, removing, adding, or altering genes and modifying the DNA, are providing an impetus to the market growth. In line with this, the widespread adoption of gene therapy for the treatment of hemoglobinopathy is favoring market growth. Other factors, such as the significant expansion in the healthcare industry, along with the implementation of various government initiatives to promote research and development (R&D) activities to introduce novel therapies for treating hemoglobinopathies at affordable costs is anticipated to provide a positive outlook for the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global hemoglobinopathies market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on type, treatment, test type and end user.

Breakup by Type:

Thalassemia

Alpha Thalassemia

Beta Thalassemia

Sickle Cell Disease

Others

Breakup by Treatment:

Hemoglobinopathies Market Trends:



The increasing prevalence of various medical conditions, such as sickle cell disease (SCD) and thalassemia, is one of the key factors driving the growth of the market. Hemoglobinopathies are caused by abnormal hemoglobin that deforms and damages red blood cells and makes them hard and sticky. In line with this, the rising prevalence of anemia, especially among the geriatric population, which is also susceptible to various other chronic ailments, is favoring the market growth. Various technological advancements, such as the development of CRISPR-Cas9 technology to cure hemoglobinopathies by editing, removing, adding, or altering genes and modifying the DNA, are providing an impetus to the market growth. In line with this, the widespread adoption of gene therapy for the treatment of hemoglobinopathy is favoring market growth. Other factors, such as the significant expansion in the healthcare industry, along with the implementation of various government initiatives to promote research and development (R&D) activities to introduce novel therapies for treating hemoglobinopathies at affordable costs is anticipated to provide a positive outlook for the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global hemoglobinopathies market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on type, treatment, test type and end user.

Breakup by Type:

Thalassemia

Alpha Thalassemia

Beta Thalassemia

Sickle Cell Disease

Others

Breakup by Treatment:

Blood Transfusion

Stem-cell Transplantation

Analgesics

Antibiotics

ACE Inhibitors

Hydroxyurea

Others

Breakup by Test Type:

Red Blood Cell (RBC) Count

Genetic Testing

High Performance Liquid Chromatography (HPLC)

Hemoglobin Isoelectric Focusing (Hb IEF)

Hemoglobin Electrophoresis (Hb ELP)

Hemoglobin Solubility Test

Breakup by End User:

Hospitals and Clinics

Diagnostics Laboratories

Others

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Bio-Rad Laboratories Inc., bluebird bio Inc., Bristol-Myers Squibb Company, Danaher Corporation, Emmaus Life Sciences Inc., Gamida-Cell Ltd., Global Blood Therapeutics Inc., Novartis AG, PerkinElmer Inc., Pfizer Inc., Prolong Pharmaceuticals LLC, Sangamo Therapeutics Inc. and Sysmex Corporation.

Key Questions Answered in This Report

1. What was the size of the global hemoglobinopathies market in 2022?

2. What is the expected growth rate of the global hemoglobinopathies market during 2023-2028?

3. What has been the impact of COVID-19 on the global hemoglobinopathies market?

4. What are the key factors driving the global hemoglobinopathies market?

5. What is the breakup of the global hemoglobinopathies market based on the type?

6. What is the breakup of the global hemoglobinopathies market based on the treatment?

7. What are the key regions in the global hemoglobinopathies market?

8. Who are the key players/companies in the global hemoglobinopathies market?

Table of Contents

143 Pages
1 Preface
2 Scope and Methodology
  2.1 Objectives of the Study
  2.2 Stakeholders
  2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
  2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
  2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
  4.1 Overview
  4.2 Key Industry Trends
5 Global Hemoglobinopathies Market
  5.1 Market Overview
  5.2 Market Performance
  5.3 Impact of COVID-19
  5.4 Market Forecast
6 Market Breakup by Type
  6.1 Thalassemia
6.1.1 Market Trends
6.1.2 Key Segments
6.1.2.1 Alpha Thalassemia
6.1.2.2 Beta Thalassemia
6.1.3 Market Forecast
  6.2 Sickle Cell Disease
6.2.1 Market Trends
6.2.2 Market Forecast
  6.3 Others
6.3.1 Market Trends
6.3.2 Market Forecast
7 Market Breakup by Treatment
  7.1 Blood Transfusion
7.1.1 Market Trends
7.1.2 Market Forecast
  7.2 Stem-cell Transplantation
7.2.1 Market Trends
7.2.2 Market Forecast
  7.3 Analgesics
7.3.1 Market Trends
7.3.2 Market Forecast
  7.4 Antibiotics
7.4.1 Market Trends
7.4.2 Market Forecast
  7.5 ACE Inhibitors
7.5.1 Market Trends
7.5.2 Market Forecast
  7.6 Hydroxyurea
7.6.1 Market Trends
7.6.2 Market Forecast
  7.7 Others
7.7.1 Market Trends
7.7.2 Market Forecast
8 Market Breakup by Test Type
  8.1 Red Blood Cell (RBC) Count
8.1.1 Market Trends
8.1.2 Market Forecast
  8.2 Genetic Testing
8.2.1 Market Trends
8.2.2 Market Forecast
  8.3 High Performance Liquid Chromatography (HPLC)
8.3.1 Market Trends
8.3.2 Market Forecast
  8.4 Hemoglobin Isoelectric Focusing (Hb IEF)
8.4.1 Market Trends
8.4.2 Market Forecast
  8.5 Hemoglobin Electrophoresis (Hb ELP)
8.5.1 Market Trends
8.5.2 Market Forecast
  8.6 Hemoglobin Solubility Test
8.6.1 Market Trends
8.6.2 Market Forecast
9 Market Breakup by End User
  9.1 Hospitals and Clinics
9.1.1 Market Trends
9.1.2 Market Forecast
  9.2 Diagnostics Laboratories
9.2.1 Market Trends
9.2.2 Market Forecast
  9.3 Others
9.3.1 Market Trends
9.3.2 Market Forecast
10  Market Breakup by Region
  10.1 North America
10.1.1 United States
10.1.1.1 Market Trends
10.1.1.2 Market Forecast
10.1.2 Canada
10.1.2.1 Market Trends
10.1.2.2 Market Forecast
  10.2 Asia-Pacific
10.2.1 China
10.2.1.1 Market Trends
10.2.1.2 Market Forecast
10.2.2 Japan
10.2.2.1 Market Trends
10.2.2.2 Market Forecast
10.2.3 India
10.2.3.1 Market Trends
10.2.3.2 Market Forecast
10.2.4 South Korea
10.2.4.1 Market Trends
10.2.4.2 Market Forecast
10.2.5 Australia
10.2.5.1 Market Trends
10.2.5.2 Market Forecast
10.2.6 Indonesia
10.2.6.1 Market Trends
10.2.6.2 Market Forecast
10.2.7 Others
10.2.7.1 Market Trends
10.2.7.2 Market Forecast
  10.3 Europe
10.3.1 Germany
10.3.1.1 Market Trends
10.3.1.2 Market Forecast
10.3.2 France
10.3.2.1 Market Trends
10.3.2.2 Market Forecast
10.3.3 United Kingdom
10.3.3.1 Market Trends
10.3.3.2 Market Forecast
10.3.4 Italy
10.3.4.1 Market Trends
10.3.4.2 Market Forecast
10.3.5 Spain
10.3.5.1 Market Trends
10.3.5.2 Market Forecast
10.3.6 Russia
10.3.6.1 Market Trends
10.3.6.2 Market Forecast
10.3.7 Others
10.3.7.1 Market Trends
10.3.7.2 Market Forecast
  10.4 Latin America
10.4.1 Brazil
10.4.1.1 Market Trends
10.4.1.2 Market Forecast
10.4.2 Mexico
10.4.2.1 Market Trends
10.4.2.2 Market Forecast
10.4.3 Others
10.4.3.1 Market Trends
10.4.3.2 Market Forecast
  10.5 Middle East and Africa
10.5.1 Market Trends
10.5.2 Market Breakup by Country
10.5.3 Market Forecast
11  SWOT Analysis
  11.1 Overview
  11.2 Strengths
  11.3 Weaknesses
  11.4 Opportunities
  11.5 Threats
12  Value Chain Analysis
13  Porters Five Forces Analysis
  13.1 Overview
  13.2 Bargaining Power of Buyers
  13.3 Bargaining Power of Suppliers
  13.4 Degree of Competition
  13.5 Threat of New Entrants
  13.6 Threat of Substitutes
14  Price Analysis
15  Competitive Landscape
  15.1 Market Structure
  15.2 Key Players
  15.3 Profiles of Key Players
15.3.1 Bio-Rad Laboratories Inc.
15.3.1.1 Company Overview
15.3.1.2 Product Portfolio
15.3.1.3 Financials
15.3.1.4 SWOT Analysis
15.3.2 bluebird bio Inc.
15.3.2.1 Company Overview
15.3.2.2 Product Portfolio
15.3.2.3 Financials
15.3.2.4 SWOT Analysis
15.3.3 Bristol-Myers Squibb Company
15.3.3.1 Company Overview
15.3.3.2 Product Portfolio
15.3.3.3 Financials
15.3.3.4 SWOT Analysis
15.3.4 Danaher Corporation
15.3.4.1 Company Overview
15.3.4.2 Product Portfolio
15.3.4.3 Financials
15.3.4.4 SWOT Analysis
15.3.5 Emmaus Life Sciences Inc.
15.3.5.1 Company Overview
15.3.5.2 Product Portfolio
15.3.5.3 Financials
15.3.6 Gamida-Cell Ltd.
15.3.6.1 Company Overview
15.3.6.2 Product Portfolio
15.3.6.3 Financials
15.3.7 Global Blood Therapeutics Inc.
15.3.7.1 Company Overview
15.3.7.2 Product Portfolio
15.3.7.3 Financials
15.3.8 Novartis AG
15.3.8.1 Company Overview
15.3.8.2 Product Portfolio
15.3.8.3 Financials
15.3.8.4 SWOT Analysis
15.3.9 PerkinElmer Inc.
15.3.9.1 Company Overview
15.3.9.2 Product Portfolio
15.3.9.3 Financials
15.3.9.4 SWOT Analysis
15.3.10 Pfizer Inc.
15.3.10.1 Company Overview
15.3.10.2 Product Portfolio
15.3.10.3 Financials
15.3.10.4 SWOT Analysis
15.3.11 Prolong Pharmaceuticals LLC
15.3.11.1 Company Overview
15.3.11.2 Product Portfolio
15.3.12 Sangamo Therapeutics Inc.
15.3.12.1 Company Overview
15.3.12.2 Product Portfolio
15.3.12.3 Financials
15.3.12.4 SWOT Analysis
15.3.13 Sysmex Corporation
15.3.13.1 Company Overview
15.3.13.2 Product Portfolio
15.3.13.3 Financials
15.3.13.4 SWOT Analysis

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us